Cancer Biomark. 2025 Dec;42(12):18758592251390251. doi: 10.1177/18758592251390251. Epub 2025 Dec 5.
ABSTRACT
PurposeVenous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a leading cause of morbidity and mortality in cancer patients. Prostate cancer is associated with an elevated risk of VTE, yet the molecular drivers remain poorly defined.MethodsIn this study, we employed high-throughput proteomic profiling using the SomaLogic platform to analyze plasma from 85 prostate cancer patients, including 43 with and 42 without VTE. Samples were collected at cancer diagnosis, with VTE diagnosed at a mean of 96.8 months later.ResultsPrincipal component analysis showed modest proteomic separation between groups. Differential expression analysis identified enriched pathways in VTE patients, including hemostasis (TIMP1, JAM2, TMX3, F3, and ESAM), cell adhesion (CXCL12, CCL11, CCN5, COL18A1, and ADGRB1) and cell proliferation (TIMP1, REG1B, REG1A, CRLF2, and ALDH1A2). Receiver Operating Characteristic analysis using top fifteen proteins achieved an area under the curve of 0.859, indicating strong predictive value for VTE in this cohort.ConclusionsWe identified a specific cluster of circulating proteins associated with development of VTE in patients with prostate cancer. This work deepens understanding of systemic mediators of cancer-associated VTE and, pending validation in other cohorts, paves the way for improved risk stratification and long-term monitoring in this population.
PMID:41348521 | DOI:10.1177/18758592251390251